Ark Therapeutics plans UK listing for up to $57 million
This article was originally published in Clinica
UK company Ark Therapeutics, which develops medical products and pharmaceuticals aimed at vascular disease and cancer, aims to raise £30-40 million ($43-57 million) through its flotation on the London Stock Exchange.
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.